Telix Pharmaceut Financials
This page shows Telix Pharmaceut (TLPPF) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Telix Pharmaceut's revenue surged 55.6% year-over-year to $803.8M, reflecting rapid business expansion. This strong growth earns a score of 100/100.
Telix Pharmaceut carries a low D/E ratio of 0.14, meaning only $0.14 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 99/100, indicating a strong balance sheet with room for future borrowing.
Telix Pharmaceut's current ratio of 1.43 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 24/100, which could limit financial flexibility.
While Telix Pharmaceut generated -$17.3M in operating cash flow, capex of $25.7M consumed most of it, leaving -$43.0M in free cash flow. This results in a low score of 12/100, reflecting heavy capital investment rather than weak cash generation.
Telix Pharmaceut generates a -1.7% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 7/100. This is down from 9.5% the prior year.
Telix Pharmaceut passes 1 of 9 financial strength tests. No profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
For every $1 of reported earnings, Telix Pharmaceut generates $2.43 in operating cash flow (-$17.3M OCF vs -$7.1M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Telix Pharmaceut generated $803.8M in revenue in fiscal year 2025. This represents an increase of 55.6% from the prior year.
Telix Pharmaceut reported -$7.1M in net income in fiscal year 2025. This represents a decrease of 121.2% from the prior year.
Telix Pharmaceut earned $-0.02 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 121.6% from the prior year.
Cash & Balance Sheet
Telix Pharmaceut generated -$43.0M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 334.0% from the prior year.
Telix Pharmaceut held $141.9M in cash against $56.5M in long-term debt as of fiscal year 2025.
Telix Pharmaceut had 339M shares outstanding in fiscal year 2025. This represents an increase of 1.2% from the prior year.
Margins & Returns
Telix Pharmaceut's net profit margin was -0.9% in fiscal year 2025, showing the share of revenue converted to profit. This is down 7.4 percentage points from the prior year.
Telix Pharmaceut's ROE was -1.7% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 11.3 percentage points from the prior year.
Capital Allocation
Telix Pharmaceut invested $25.7M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 181.8% from the prior year.
TLPPF Income Statement
| Metric | Q4'25 | Q4'24 | Q4'23 |
|---|---|---|---|
| Revenue | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A |
| R&D Expenses | N/A | N/A | N/A |
| SG&A Expenses | N/A | N/A | N/A |
| Operating Income | N/A | N/A | N/A |
| Interest Expense | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A |
| Net Income | N/A | N/A | N/A |
| EPS (Diluted) | N/A | N/A | N/A |
TLPPF Balance Sheet
| Metric | Q4'25 | Q4'24 | Q4'23 |
|---|---|---|---|
| Total Assets | $1.2B+23.8% | $940.4M+239.2% | $277.3M |
| Current Assets | $330.3M-42.1% | $570.1M+259.3% | $158.7M |
| Cash & Equivalents | $141.9M-67.8% | $440.0M+422.0% | $84.3M |
| Inventory | $37.1M+57.0% | $23.6M+85.4% | $12.7M |
| Accounts Receivable | $129.2M+48.6% | $86.9M+97.4% | $44.0M |
| Goodwill | $199.0M+198.8% | $66.6M-11.3% | $75.1M |
| Total Liabilities | $748.6M+27.4% | $587.4M+236.4% | $174.6M |
| Current Liabilities | $231.6M+12.9% | $205.1M+84.1% | $111.4M |
| Long-Term Debt | $56.5M+1021.3% | $5.0M-4.0% | $5.3M |
| Total Equity | $415.4M+17.7% | $352.9M+243.8% | $102.6M |
| Retained Earnings | -$154.5M-1.1% | -$152.9M+18.3% | -$187.1M |
TLPPF Cash Flow Statement
| Metric | Q4'25 | Q4'24 | Q4'23 |
|---|---|---|---|
| Operating Cash Flow | N/A | N/A | N/A |
| Capital Expenditures | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A |
| Financing Cash Flow | N/A | N/A | N/A |
| Dividends Paid | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A |
TLPPF Financial Ratios
| Metric | Q4'25 | Q4'24 | Q4'23 |
|---|---|---|---|
| Gross Margin | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A |
| Current Ratio | 1.43-1.4 | 2.78+1.4 | 1.42 |
| Debt-to-Equity | 0.14+0.1 | 0.01-0.0 | 0.05 |
| FCF Margin | N/A | N/A | N/A |
Frequently Asked Questions
What is Telix Pharmaceut's annual revenue?
Telix Pharmaceut (TLPPF) reported $803.8M in total revenue for fiscal year 2025. This represents a 55.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Telix Pharmaceut's revenue growing?
Telix Pharmaceut (TLPPF) revenue grew by 55.6% year-over-year, from $516.6M to $803.8M in fiscal year 2025.
Is Telix Pharmaceut profitable?
No, Telix Pharmaceut (TLPPF) reported a net income of -$7.1M in fiscal year 2025, with a net profit margin of -0.9%.
How much debt does Telix Pharmaceut have?
As of fiscal year 2025, Telix Pharmaceut (TLPPF) had $141.9M in cash and equivalents against $56.5M in long-term debt.
What is Telix Pharmaceut's net profit margin?
Telix Pharmaceut (TLPPF) had a net profit margin of -0.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Telix Pharmaceut's return on equity (ROE)?
Telix Pharmaceut (TLPPF) has a return on equity of -1.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Telix Pharmaceut's free cash flow?
Telix Pharmaceut (TLPPF) generated -$43.0M in free cash flow during fiscal year 2025. This represents a -334.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Telix Pharmaceut's operating cash flow?
Telix Pharmaceut (TLPPF) generated -$17.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Telix Pharmaceut's total assets?
Telix Pharmaceut (TLPPF) had $1.2B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Telix Pharmaceut's capital expenditures?
Telix Pharmaceut (TLPPF) invested $25.7M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Telix Pharmaceut's current ratio?
Telix Pharmaceut (TLPPF) had a current ratio of 1.43 as of fiscal year 2025, which is considered adequate.
What is Telix Pharmaceut's debt-to-equity ratio?
Telix Pharmaceut (TLPPF) had a debt-to-equity ratio of 0.14 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Telix Pharmaceut's return on assets (ROA)?
Telix Pharmaceut (TLPPF) had a return on assets of -0.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Telix Pharmaceut's cash runway?
Based on fiscal year 2025 data, Telix Pharmaceut (TLPPF) had $141.9M in cash against an annual operating cash burn of $17.3M. This gives an estimated cash runway of approximately 98 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Telix Pharmaceut's Piotroski F-Score?
Telix Pharmaceut (TLPPF) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Telix Pharmaceut's earnings high quality?
Telix Pharmaceut (TLPPF) has an earnings quality ratio of 2.43x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Telix Pharmaceut?
Telix Pharmaceut (TLPPF) scores 48 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.